Literature DB >> 11474782

Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa.

A Lamprecht1, U Schäfer, C M Lehr.   

Abstract

PURPOSE: The size-dependent deposition of microparticles and nanoparticles after oral administration to rats using an experimental model colitis was examined. Local delivery of an entrapped drug could reduce side effects and would be a distinct improvement compared with existing colon delivery devices.
METHODS: Ulcerative colitis was induced in Lewis rats with trinitrobenzenesulfonic acid. Fluorescent polystyrene particles with a size of 0.1, 1, or 10 microm were administered for 3 days. The animals then were sacrificed and their guts resected. Particle distribution in the colon was imaged by confocal laser scanning microscopy and quantified by fluorescence spectrophotometry.
RESULTS: In the inflamed tissue, an increased adherence of particles was observed at the thicker mucus layer and in the ulcerated regions. A size dependency of the deposition was found, and an increased number of attached particles to the colon was determined compared with the control group. For 10-micorm particles, only fair deposition was observed (control group: 1.4 +/- 0.6%; colitis: 5.2 +/- 3.8% of administered particle mass). One-micrometer particles showed higher binding (control group: 2.0 +/- 0.8%; colitis: 9.1 +/- 4.2%). Highest binding was found for 0.1-microm particles (control group: 2.2 +/- 1.6%; colitis: 14.5 +/- 6.3%). The ratio of colitis/control deposition increased with smaller particle sizes.
CONCLUSIONS: The use of submicron-sized carriers holds promise for the targeted delivery of drugs to the inflamed colonic mucosal areas in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474782     DOI: 10.1023/a:1011032328064

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Migration of adhesive and nonadhesive particles in the rat intestine under altered mucus secretion conditions.

Authors:  B Tirosh; A Rubinstein
Journal:  J Pharm Sci       Date:  1998-04       Impact factor: 3.534

2.  Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastrointestinal tract.

Authors:  S Sakuma; R Sudo; N Suzuki; H Kikuchi; M Akashi; M Hayashi
Journal:  Int J Pharm       Date:  1999-01-25       Impact factor: 5.875

3.  Colon-specific delivery of budesonide with azopolymer-coated pellets: therapeutic effects of budesonide with a novel dosage form against 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats.

Authors:  H Tozaki; T Fujita; J Komoike; S I Kim; H Terashima; S Muranishi; S Okabe; A Yamamoto
Journal:  J Pharm Pharmacol       Date:  1999-03       Impact factor: 3.765

Review 4.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

5.  Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region.

Authors:  M Rodríguez; J L Vila-Jato; D Torres
Journal:  J Control Release       Date:  1998-10-30       Impact factor: 9.776

6.  Uptake of nanoparticles by rat glomerular mesangial cells in vivo and in vitro.

Authors:  L Manil; J C Davin; C Duchenne; C Kubiak; J Foidart; P Couvreur; P Mahieu
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

7.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models.

Authors:  J E Krawisz; P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

8.  Mechanisms of action of sucralfate.

Authors:  R Nagashima
Journal:  J Clin Gastroenterol       Date:  1981       Impact factor: 3.062

9.  Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency.

Authors:  P Jani; G W Halbert; J Langridge; A T Florence
Journal:  J Pharm Pharmacol       Date:  1990-12       Impact factor: 3.765

10.  Intracellular visualization of ampicillin-loaded nanoparticles in peritoneal macrophages infected in vitro with Salmonella typhimurium.

Authors:  H Pinto-Alphandary; O Balland; M Laurent; A Andremont; F Puisieux; P Couvreur
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

View more
  80 in total

Review 1.  Approaching the asymptote: obstacles and opportunities for nanomedicine in cardiovascular disease.

Authors:  Sascha N Goonewardena
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

Review 2.  Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.

Authors:  Madharasi V A Pichai; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

Review 3.  Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers.

Authors:  Mary Caldorera-Moore; Nathalie Guimard; Li Shi; Krishnendu Roy
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

Review 4.  Nanomedicine in GI.

Authors:  Hamed Laroui; David S Wilson; Guillaume Dalmasso; Khalid Salaita; Niren Murthy; Shanthi V Sitaraman; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-09       Impact factor: 4.052

5.  Drug Release and Targeting: the Versatility of Polymethacrylate Nanoparticles for Peroral Administration Revealed by Using an Optimized In Vitro-Toolbox.

Authors:  Susanne Beyer; Aline Moosmann; Astrid S Kahnt; Thomas Ulshöfer; Michael J Parnham; Nerea Ferreirós; Sylvia Wagner; Matthias G Wacker
Journal:  Pharm Res       Date:  2015-07-28       Impact factor: 4.200

6.  Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles.

Authors:  Hamed Laroui; Duke Geem; Bo Xiao; Emilie Viennois; Poonam Rakhya; Timothy Denning; Didier Merlin
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

7.  Functional TNFα gene silencing mediated by polyethyleneimine/TNFα siRNA nanocomplexes in inflamed colon.

Authors:  Hamed Laroui; Arianne L Theiss; Yutao Yan; Guillaume Dalmasso; Hang T T Nguyen; Shanthi V Sitaraman; Didier Merlin
Journal:  Biomaterials       Date:  2011-02       Impact factor: 12.479

Review 8.  Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers.

Authors:  Julie A Champion; Yogesh K Katare; Samir Mitragotri
Journal:  J Control Release       Date:  2007-04-11       Impact factor: 9.776

9.  Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model.

Authors:  Filippos Kesisoglou; Simon Yuji Zhou; Susan Niemiec; Jordan Wing Lee; Ellen M Zimmermann; David Fleisher
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

10.  Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry.

Authors:  Lee Jia; Hong Wong; Cesario Cerna; Steve D Weitman
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.